The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance

SIMPLE SUMMARY: Cyclin-dependent kinase inhibitors (palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)), targeting aberrant cell-cycle activity have been evaluated extensively in clinical trials. Significant delays in progression free survival and overall survival are now docume...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmalak, Mary, Singh, Rajanbir, Anwer, Mohammed, Ivanchenko, Pavel, Randhawa, Amritdeep, Ahmed, Myra, Ashton, Anthony W., Du, Yanming, Jiao, Xuanmao, Pestell, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655989/
https://www.ncbi.nlm.nih.gov/pubmed/36358806
http://dx.doi.org/10.3390/cancers14215388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655989/
https://www.ncbi.nlm.nih.gov/pubmed/36358806
http://dx.doi.org/10.3390/cancers14215388

Ejemplares similares